Last reviewed · How we verify
NCR100
At a glance
| Generic name | NCR100 |
|---|---|
| Sponsor | Nuwacell Biotechnologies Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution (PHASE1)
- A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA） (PHASE1, PHASE2)
- A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NCR100 CI brief — competitive landscape report
- NCR100 updates RSS · CI watch RSS
- Nuwacell Biotechnologies Co., Ltd. portfolio CI